Sign in
Taking people in South KoreaPhase 4

Tests dapagliflozin or pioglitazone added to metformin and DPP-4 inhibitor in type 2 diabetes

Tests dapagliflozin or pioglitazone added to standard drugs in adults with type 2 diabetes.

Key facts

Who runs it
Dong Wha Pharmaceutical Co. Ltd.
Where
Seoul, South KoreaSee the site
Trial code
Registry title
DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes
Status
Recruiting
Phase
Phase 4
People taking part
196 people, planned
Started
28 May 2024
Planned end
31 Dec 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • DW6012(Dasidiem tab. 10/100mg)
Record updated
17 March 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes whose blood sugar is not well controlled on metformin plus a DPP-4 inhibitor.

Age
19 years or older
Sex
All sexes can join
Disease stage
Type 2 diabetes with HbA1c from 7.0% (53 mmol/mol) up to less than 10% (86 mmol/mol), and BMI up to 40 kg/m2
Earlier treatment
Must have taken a stable dose of metformin and a DPP-4 inhibitor for at least the last 8 weeks. Must not have used insulin, sulfonylurea, thiazolidinedione, SGLT2 inhibitor or GLP-1 receptor agonist in the 8 weeks before screening.

Main reasons for not taking part

  • Type 1 diabetes
  • Moderate or severe kidney disease (eGFR below 45 mL/min/1.73 m2), end stage kidney disease or dialysis
  • Uncontrolled heart failure (NYHA class III - IV)
  • History of ketoacidosis or metabolic acidosis
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Patients with type 2 diabetes who are 19 years of age or older at the date of written consent
  • Subjects who Receiving a stable dose of metformin and a DPP-4 inhibitor for at least the last 8 weeks at the time of screening
  • HbA1c ≤ 7.0% ≤ HbA1c < 10% at time of screening
  • BMI ≤ 18.5 kg/m2 ≤ 40 kg/m2 at time of screening
  • Subjects fully explained and understood the purpose and methods of this study and voluntarily gave written informed consent

Who cannot take part

  • Patients with history of uncontrolled arrhythmia, myocardial infarction, unstable angina, coronary artery bypass graft surgery, cerebrovascular disease within 24 weeks prior to the screening visit
  • Patients who receiving treatment for thyroid dysfunction at the time of screening
  • Patients receiving insulin or sulfonylurea, thiazolidinedione, SGLT2 inhibitor, GLP-1 receptor agonist within 8 weeks prior to the screening visit
  • Patients who have received more than 2 consecutive weeks of corticosteroids within 8 weeks at the time of screening or who require treatment requiring repeated use of corticosteroids
  • Participation in any other clinical trial within 12 weeks of screening in which an investigational drug or investigational medical device was administered or applied
  • Patients with type 1 diabetes
  • Patients with end stage renal disease or patients on dialysis
  • Patients with uncontrolled heart failure (NYHA class III - IV)
  • Patients with acute or chronic metabolic acidosis, including lactic acidosis, diabetic ketoacidosis (DKA) with or without coma, and patients with a history of ketoacidosis
  • Patients with a history of severe hypoglycemia while taking metformin and DPP-4 inhibitors
  • Patients with pituitary insufficiency or adrenal insufficiency
  • Patients with severe infectious diseases, perioperative, or clinically significant trauma
  • Have a history of substance abuse
  • Patients with a history of malignancy within the last 5 years
  • Hypersensitivity to any of the drugs and components, including metformin, DPP-4 inhibitors, dapagliflozin, TZDs, sulfonylurea class of drugs, or any of the ingredients
  • Subjects who have moderate (Stage 3b) or severe kidney disease or an estimated glomerular filtration rate (eGFR, using the CKD-EPI formula) < 45 mL/min/1.73 m2
  • Patients with clinically significant hepatic disease with AST or ALT greater than 3 times the upper limit of normal
  • Patients with genetic problems such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose mal-absorption
  • Have a BMI > 40 kg/m2
  • Patients with diabetic coma or precoma
  • Patients with hematuria
  • Malnourished, starving, or debilitated subjects
  • Pregnant and breastfeeding women
  • Any other person deemed by the investigator to be unsuitable for participation in the study

Where in South Korea

  • Kyung Hee University Hospital at GangdongSeoul, South KoreaContact: Kyung Hee University Hospital at GangdongTaking people

About the trial

What the trial wants to find out

Key finding of DM Treatment with combination, A MuLticenter, Randomized, Parallel, Gathering Information of phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone add-on to Metformin and DPP-4 inhibitor in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and DPP-4 inhibitor(KLIMT Study)

The 2 groups in the trial

  • Dasidiem 10/100mgTreatment being tested

    Dapagliflozin 10mg +sitagliptin 100mg combination drug

    Treatment: DW6012(Dasidiem tab. 10/100mg)

  • sitdiem 100mg, Piotazone15mgExisting treatment, for comparison

    sitagliptin 100mg, Pioglitazone 15mg

    Treatment: DW6012(Dasidiem tab. 10/100mg)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Key Finding of DM Treatment with Combination, a MuLticenter, Randomized, Parallel, Gathering Information of Phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone Add-on to Metformin and DPP-4 Inhibitor in Patients with Type 2 Diabetes
Plain-language title
Tests dapagliflozin or pioglitazone added to metformin and DPP-4 inhibitor in type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 March 2025